Proinsulin, Intact
Proinsulin is the precursor of insulin and an important marker of pancreatic beta-cell function. It is synthesized as preproinsulin, which undergoes cleavage in the endoplasmic reticulum to form proinsulin. Proinsulin consists of an A chain, a B chain, and a connecting peptide (C-peptide). In the Golgi apparatus, prohormone convertases cleave proinsulin to release active insulin (A and B chains linked by disulfide bonds) and C-peptide in equimolar amounts.
Under normal physiological conditions, proinsulin constitutes only a small fraction (<20%) of total circulating immunoreactive insulin. However, in insulin-producing tumors (insulinomas) and in insulin resistance states, circulating proinsulin concentrations can be disproportionately elevated. In type 1 diabetes mellitus, destruction of pancreatic beta cells results in very low or absent proinsulin levels. In type 2 diabetes mellitus, due to insulin resistance and compensatory beta-cell stress, proinsulin levels may rise significantly. Thus, proinsulin measurement provides insights into beta-cell reserve, secretory dynamics, and pathological processes.
- Evaluation of pancreatic beta-cell function
- As an aid in the diagnosis of insulin-producing tumors (insulinoma)
- Differentiating type 1 from type 2 diabetes mellitus
- Monitoring disease progression and treatment efficacy in type 2 diabetes mellitus
- Assessment of insulin resistance and metabolic syndrome
Increased in:
- Type 2 diabetes mellitus
- Insulinomas
- Obesity and metabolic syndrome
- Beta-cell dysfunction and insulin resistance states
- Gestational diabetes mellitus
- Long-term corticosteroid therapy
Decreased in:
- Type 1 diabetes mellitus (due to autoimmune beta-cell destruction)
- Advanced beta-cell failure (late-stage diabetes)
3.6-22 pmol/L
Electrochemiluminescent immunoassay (ECLIA) is the most widely used technique. Other available methods include radioimmunoassay (RIA) and ELISA.
Plasma, EDTA.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 30 days
Glucose, insulin, C-peptide, HbA1c, oral glucose tolerance test (OGTT), comprehensive metabolic panel, electrolytes, thyroid-stimulating hormone (TSH), CBC, urinalysis, and procalcitonin (if infection/inflammation suspected).
2 to 5 days.
- Metabolism. 1977 May;26(5):547-87. [PMID: 403392]
- Diabetes Care. 2019 Feb;42(2):258-264. [PMID: 30530850]
- J Clin Endocrinol Metab. 2013 Dec;98(12):4752-8. [PMID: 24081736]
- Metabolism. 1986 Dec;35(12):1137-46. [PMID: 3023795]
- Recent Prog Horm Res. 1976;33:435-75. [PMID: 198859]